Leadership - Allinky Biopharma

ALLINKY Biopharma
Go to content

Shaping the future of Medicine


Miguel Vega MEng, PDD-IESE
• Partner & General Manager.
• 25 Years of R&D and BD experience: Spanish National Genomic Foundation, UAM, European Commission.
• Former institutional investor in Sanifit, Genmedica, Bioncotech, VCN Biosciences and many others.

Diego Labarquilla MEng, MBA-Insead
• Partner & Business Advisor.
• President of Savera Group.
• Former corporate investor in Tigenix, recently acquired by Takeda.

Prof. Juan Gómez-Reino, MD
• Partner& Scientific Advisor.
• Former Head of Rheumatology at the University Hospital – Santiago de Compostela.
• 40 years of experience in clinical research.
• Former clinical advisor to top pharmaceutical companies.

Prof. Balbino Alarcón
• Partner & Scientific Advisor.
• Full Research Professor at the National Research Council (CSIC) – Madrid.
• 30 years of experience in R&D.
• Scientific advisor to Artax Biopharma.

Prof. Ángel Messeguer
• Partner & Scientific Advisor.
• Full Research Professor at the National Research Council (CSIC) – Barcelona.
• 40 years of experience in Medicinal Chemistry.
• Former scientific advisor to Menarini, Lipotec and Salvat.

Prof. Juan Jesús Pérez
• Chair Dept of Chemical Engineering, Polytechnic University of Catalonia – Barcelona.
• 30 years of experience in Computational Chemistry.
• Former scientific advisor to Ferrer, Menarini and Salvat.

Prof. Ignacio Torres Alemán
• Partner & Scientific Advisor.
• Full Research Professor at the National Research Council (CSIC) - Madrid
• 30 years of experience in R&D.
• Former scientific advisor to Takeda, Roche and Fonterra.


Dept. of Computational Chemistry
  • Accelerated Molecular Dynamics
  • Ensemble docking and in silico drug screening
  • NMR studies
  • Protein crystallization studies

Patricia Gómez Ph.D.
  • Head of Computational Chemistry
  • 7 years experience in drug design and molecular modeling

Dept. of Molecular & Cell Biology
  • Target validation, mutagenesis and purification
  • in vitro and in vivo compound screening
  • Animal efficacy studies

Pedro Campos Ph.D.
  • Head of Molecular Biology
  • 7 years experience in the biology of drug discovery

Dept. of Medicinal Chemistry
  • Novel structure synthesis
  • Site-directed combinatorial chemistry  for lead optimization

Esther Carrasco Ph.D.
  • Head of MedChem (inflammation)
  • 9 years experience in Medicinal Chemistry

Asunción Burguete Ph.D.
  • Head of MedChem (oncology)
  • 7 years experience in Medicinal Chemistry

  • R-Ras2 is required for germinal center formation to aid B cells during energetically demanding processes. Sci Signal. 2018 May
  • Validation study of genetic biomarkers of response to TNF inhibitors in rheumatoid arthritis. PLoS One. 2018 May
  • Replication study of polymorphisms associated with response to methotrexate in patients with rheumatoid arthritis. Sci Rep. 2018 May
  • Flavonoid allosteric modulation of mutated visual rhodopsin associated with retinitis pigmentosa. Sci Rep. 2017 Sep
  • Insulin Regulates Astrocytic Glucose Handling Through Cooperation With IGF-I. Diabetes. 2017 Jan
  • Astrocytic Insulin Signaling Couples Brain Glucose Uptake with Nutrient Availability. Cell, 2016 Aug
  • A Cholesterol-Based Allostery Model of T Cell Receptor Phosphorylation. Immunity, 2016 May
  • Blockade of the Interaction of Calcineurin with FOXO in Astrocytes Protects Against Amyloid-β-Induced Neuronal Death. J Alzheimers Dis, 2016 Apr
  • Neuronal death by oxidative stress involves activation of FOXO3 through a two-arm pathway that activates stress kinases and attenuates insulin-like growth factor I signaling. Mol Biol Cell, 2008 May
  • Phosphatidylinositol 3-kinase, MEK-1 and p38 mediate leptin/interferon-gamma synergistic NOS type II induction in chondrocytes. Life Sci, 2007 Oct
Back to content